VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants

Viruses. 2023 Jun 13;15(6):1364. doi: 10.3390/v15061364.

Abstract

Since the emergence of the original SARS-CoV-2, several variants were described, raising questions as to the ability of recently developed vaccine platforms to induce immunity and provide protection against these variants. Here, we utilized the K18-hACE2 mouse model to show that VSV-ΔG-spike vaccination provides protection against several SARS-CoV-2 variants: alpha, beta, gamma, and delta. We show an overall robust immune response, regardless of variant identity, leading to reduction in viral load in target organs, prevention of morbidity and mortality, as well as prevention of severe brain immune response, which follows infection with various variants. Additionally, we provide a comprehensive comparison of the brain transcriptomic profile in response to infection with different variants of SARS-CoV-2 and show how vaccination prevents these disease manifestations. Taken together, these results highlight the robust VSV-ΔG-spike protective response against diverse SARS-CoV-2 variants, as well as its promising potential against newly arising variants.

Keywords: K18-hACE2; SARS-CoV-2; VSV-ΔG-Spike; brain; vaccine; variants.

MeSH terms

  • Animals
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Mice
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus

Substances

  • K-18 conjugate
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This research received no external funding.